Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura J Esserman

Showing results (221-230 of 308) with videos related to

Pageof 31
Sort By:
Breast Cancer Research and Treatment|May 21, 2011
Biologic markers determine both the risk and the timing of recurrence in breast cancerLaura J Esserman, Dan H Moore, Pamela J Tsing, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 9, 2008
Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conferenceThomas A Buchholz, Constance D Lehman, Jay R Harris, et al.
Breast Cancer Research and Treatment|February 15, 2016
A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignanciesAmy Jo Chien, Alyson Cockerill, Craig Fancourt, et al.
Cancer Research Communications|March 27, 2023
Identifying Good Candidates for Active Surveillance of Ductal Carcinoma <i>In Situ</i>: Insights from a Large Neoadjuvant Endocrine Therapy CohortAlexa C Glencer, Phoebe N Miller, Heather Greenwood, et al.
Breast Cancer Research and Treatment|September 16, 2010
Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcomeMichael J Campbell, Nathan Y Tonlaar, Elisabeth R Garwood, et al.
Radiology. Imaging Cancer|March 29, 2024
<sup>18</sup>F-FDG Dedicated Breast PET Complementary to Breast MRI for Evaluating Early Response to Neoadjuvant ChemotherapyDevan Diwanji, Natsuko Onishi, Deep K Hathi, et al.
NPJ Breast Cancer|January 14, 2022
The breast pre-cancer atlas illustrates the molecular and micro-environmental diversity of ductal carcinoma in situDaniela Nachmanson, Adam Officer, Hidetoshi Mori, et al.
Oncotarget|March 1, 2018
Rapid detection of <i>BRCA1/2</i> recurrent mutations in Chinese breast and ovarian cancer patients with multiplex SNaPshot genotyping panelsAva Kwong, John C W Ho, Vivian Y Shin, et al.
Cancer Cytopathology|October 9, 2025
FNA biopsy of breast specimens effectively harvests cells for patient-derived organoids modeling ductal carcinoma in situJulia Ye, Nadine Goldhammer, Poonam Vohra, et al.
Tomography (Ann Arbor, Mich.)|November 26, 2024
Tumor Morphology for Prediction of Poor Responses Early in Neoadjuvant Chemotherapy for Breast Cancer: A Multicenter Retrospective StudyWen Li, Nu N Le, Rohan Nadkarni, et al.
Pageof 31

Showing results (221-230 of 308) with videos related to

Sort By:
Pageof 31
Breast Cancer Research and Treatment|May 21, 2011
Biologic markers determine both the risk and the timing of recurrence in breast cancerLaura J Esserman, Dan H Moore, Pamela J Tsing, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 9, 2008
Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conferenceThomas A Buchholz, Constance D Lehman, Jay R Harris, et al.
Breast Cancer Research and Treatment|February 15, 2016
A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignanciesAmy Jo Chien, Alyson Cockerill, Craig Fancourt, et al.
Cancer Research Communications|March 27, 2023
Identifying Good Candidates for Active Surveillance of Ductal Carcinoma <i>In Situ</i>: Insights from a Large Neoadjuvant Endocrine Therapy CohortAlexa C Glencer, Phoebe N Miller, Heather Greenwood, et al.
Breast Cancer Research and Treatment|September 16, 2010
Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcomeMichael J Campbell, Nathan Y Tonlaar, Elisabeth R Garwood, et al.
Radiology. Imaging Cancer|March 29, 2024
<sup>18</sup>F-FDG Dedicated Breast PET Complementary to Breast MRI for Evaluating Early Response to Neoadjuvant ChemotherapyDevan Diwanji, Natsuko Onishi, Deep K Hathi, et al.
NPJ Breast Cancer|January 14, 2022
The breast pre-cancer atlas illustrates the molecular and micro-environmental diversity of ductal carcinoma in situDaniela Nachmanson, Adam Officer, Hidetoshi Mori, et al.
Oncotarget|March 1, 2018
Rapid detection of <i>BRCA1/2</i> recurrent mutations in Chinese breast and ovarian cancer patients with multiplex SNaPshot genotyping panelsAva Kwong, John C W Ho, Vivian Y Shin, et al.
Cancer Cytopathology|October 9, 2025
FNA biopsy of breast specimens effectively harvests cells for patient-derived organoids modeling ductal carcinoma in situJulia Ye, Nadine Goldhammer, Poonam Vohra, et al.
Tomography (Ann Arbor, Mich.)|November 26, 2024
Tumor Morphology for Prediction of Poor Responses Early in Neoadjuvant Chemotherapy for Breast Cancer: A Multicenter Retrospective StudyWen Li, Nu N Le, Rohan Nadkarni, et al.
Pageof 31